[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Aims & Scope
Journal News
Indexing
Articles archive::
All Issues
Current Issue
Browse by Authors
In press
Browse by Keywords
For Authors::
Submission Instruction
Submission Form
For Reviewers::
Reviewers Guidelines
Registration::
Registration Form
Publication Ethics::
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
FAQ
Top 10 contents
::
ISSN
p-ISSN: 2645-8233
e-ISSN: 2645-5943
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 6, Issue 3 (Autumn 2022) ::
Iran J Cult Health Promot 2022, 6(3): 493-503 Back to browse issues page
An Evaluation of the Implementation Process of the Generic Policy and National Pharmaceutical System in I.R.Iran
Morteza Nilforoushan , Morteza Azarnoosh , Ahmad Shibani , Moona Shahbazi , Khosrow Bayati , Hesamodin Sharifnia , Hamidreza Arabloo
Academy of Medical Sciences of I.R of Iran, Tehran, Iran
Abstract:   (2719 Views)
Background:Proposed in 1979, the generic policy, aimed to provide easy access to all the more medicines, themain important result of which is reducing pharmaceutical costs and decreasing importation. Since 1999, pharma branding in Iran was initatedby pharmaceutical companies. Therefore, companies used the brand-generic name in order to maintain the market share and also sell the drugs at a higher price and gain more market share by distinguishing drug names.
Methods: In this investigation, Iran's modern pharmaceutical system and achievements after the Islamic revolution, wereinvestigated via collecting statistics and documents regarding the conditions of generic and brand-generic drugs.
Results: Despite two decades of the national pharmaceutical policy, based on generic drugs, the percentage of generic drugs decreased from 69% to 50%, from 2012to 2021and the number of brand-generic drugs increased. Among the top one hundred best-selling drugs, 38% have brand-generic names. Regardingthe financial burden and costs imposed on patients and insurance companies due toprescribing brand-generic drugs, it is estimated to have increased from 51% in 2018 to 84% in 2013 and then to 69% in 2017 compared withtotal costs.
Conclusion: In strategic documents and general policies of Iran’s health system, including the statement of the Supreme Leader, promotion of generic drugs in the health system has been approved. However, from the operational view, the trend has been to the contraryand  towards brand-generic drugs. Reasons include: product differentiation, increasing market share by introducing products and increasing the price of drugs. The desire of companies to obtain licenses with brand-generic names is based on three different policies of Iran FDA and ministry of Healththat have facilitated this issueand include: medicine naming regulations, medicines pricing regulations, marketing regulations and promotion of pharmaceutical products.
Keywords: Drug Legislation, Drug Delivery Systems, Generic Drugs, Pharmaceutical Services
Full-Text [PDF 527 kb]   (989 Downloads)    
Letter: Original Article | Subject: Special
Received: 2022/10/11 | Accepted: 2022/10/22 | ePublished ahead of print: 2022/12/11 | Published: 2022/12/21
References
1. 1.Azarnoosh M, Cheraghali A, Nilforoushan M. The evolution of Iran modern pharmaceutical system. Tehran: Asim; 2018. [In Persian]
2. 2.Azarnoosh M. Nilforoushan, M. Reviewing importing pharmaceutical products since 1977 till 2013. Tehran: Academy of Medical Sciences; 2017. [In Persian]
3. 3.General policies of the system. 2006. Islamic Parliament Research Center. Available at: https://rc.majlis.ir/fa/law/show/99709 [In Persian]
4. 4.Law of the 6th 5-year plan: economic, social and cultural development of Islamic Republic of Iran. 2017. Available at: https://ecommerce.gov.ir/uploads/ expansion6law.pdf (05/11/2022) [In Persian]
5. 5.Statement of Academy of Medical Sciences about Generic Drug Scheme and Pharmaceutical System in Iran. Iran J Cult Health Promot 2020; 3(4): 364-365. [In Persian]
6. 6.GDP per capita (current US$). 2022. The World Bank. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IR
7. 7.Álvarez R, González A, Fernández S. The Competitive Impact of Branded Generic Medicine in a Developing Country. 2019. University of Chile, Department of Economics. Available at: https://econ.uchile.cl/uploads/publicacion/89e980c45548a38714e6eda5ebabec30ade78527.pdf
8. 8.Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health 2012; 15(5): 664-73.
9. 9.Tabrizchi N, Emamgholipoor S, Abolghasem P, Etemadi M, Hosseini S, Shahedi M, et al. An Overview of Resistance Economics in the Health Sector Macro-Priority Axes and Specific Issues. Iran J Cult Health Promot 2019; 3(3): 232-249. [In Persian]
10. 10.Health at a Glance. 2017. OECD Health Statistics. Available at: https://dx.doi.org/10.1787/888933605559
11. 11.Health at a Glance. 2021. OECD Health Statistics. Available at: https://stat.link/uyjgok
12. 12.Health at a Glance. 2017. OECD Health Statistics. Available at: https://dx.doi.org/10.1787/888933605426
13. 13.Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence. 42nd ed. Washington: Department of Health and Human Services; 2022.
14. 14.Ashtarian K, Semnanian S, Jalili M. Damages and corruptions in the pharmaceutical system. 2021. Center for Strategic Studies. Available at: https://www.css.ir/Media/PDF/1399/12/24/637513240021521533.pdf [In Persian]
15. 15.Drug nomenclature regulation. 2022. Food And Drug Administration of The Islamic Republic of Iran. Available at: https://mail.syndipharma.org/ images/mehr99/zabete.pdf [In Persian]
16. 16.Pharmaceutical pricing policy. 2022. Food And Drug Administration of The Islamic Republic of Iran. Available at: https://www.fda.gov.ir/ [In Persian]
17. 17.Executive regulations on how to introduce, provide scientific information and market pharmaceutical products. 2019. Available at: https://syndipharma.org/wp-content/uploads/2019/06/tir7.pdf [In Persian]
18. 18.Electronic prescription service. Available at: https://tamin.ir/ html/item/2528 [In Persian]
19. 19.Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol 2011; 43(2): 131-6.
20. 20. Reyes CM, Lavado RF, Tabuga AD. A Profile of the Philippine Pharmaceutical Sector. 2011. Philippine Institute for Development Studies. Available at: https://pidswebs.pids.gov.ph/CDN/PUBLICATIONS/ pidsdps 1111_rev.pdf
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nilforoushan M, Azarnoosh M, Shibani A, Shahbazi M, Bayati K, Sharifnia H et al . An Evaluation of the Implementation Process of the Generic Policy and National Pharmaceutical System in I.R.Iran. Iran J Cult Health Promot 2022; 6 (3) :493-503
URL: http://ijhp.ir/article-1-631-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 6, Issue 3 (Autumn 2022) Back to browse issues page
نشريه فرهنگ و ارتقاء سلامت Iranian Journal of Culture and Health Promotion
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.09 seconds with 39 queries by YEKTAWEB 4735